Artificial Intelligence
Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies| DelveInsight
New York, USA, Jan. 25, 2023 (GLOBE NEWSWIRE) — Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies| DelveInsight
Methicillin-resistant Staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen Staphylococcus aureus. Rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA).
DelveInsight’s ‘Methicillin-Resistant Staphylococcus aureus Infection Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline methicillin-resistant Staphylococcus aureus infection therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the methicillin-resistant Staphylococcus aureus infection pipeline domain.
Key Takeaways from the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report
- DelveInsight’s methicillin-resistant Staphylococcus aureus infection pipeline report depicts a robust space with 25+ companies and 28+ pipeline drugs for methicillin-resistant Staphylococcus aureus infection treatment.
- Key methicillin-resistant Staphylococcus aureus infection companies include Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others are evaluating novel methicillin-resistant Staphylococcus aureus infection drugs candidate to improve the treatment landscape.
- Promising methicillin-resistant Staphylococcus aureus infection pipeline therapies in various stages of development include TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and several others.
- Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. In October 2022, Basilea Pharmaceutica announced the results from Phase III ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus. Results for the primary efficacy outcomes were consistent in key subgroups including in patients with MSSA or MRSA bloodstream infections at baseline, and in various categories of underlying conditions such as skin and skin structure infections, abdominal abscesses, chronic dialysis, septic arthritis, osteomyelitis, definite right-sided infective endocarditis and in patients with persistent SAB. Basilea also planned to submit a New Drug Application (NDA) for ceftobiprole to the US Food and Drug Administration (FDA) around year-end 2022.
- Exebacase (CF-301) being developed by ContraFect Corporation is a lysin with potent activity against Staphylococcus aureus (“Staph aureus”). Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. The FDA has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to SOC antistaphylococcal antibiotics in adult patients, based on the final data from the Phase II superiority trial of exebacase.
- In July 2022, Destiny Pharma plc announced that it had received an award from the Cystic Fibrosis Foundation. The research project will establish the potential of the Company’s proprietary XF-73 drug as a novel treatment for cystic fibrosis patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
- CTI-005 is for the treatment of Methicillin Resistance Staphylococcus Aureus (MRSA) Pneumonia and has been granted IND allowance from the US FDA. The potent RBC-NS has the membrane lipids and receptors that a normal red blood cell has, however, the high surface-volume ratio of the RBC-NS allows it to act as a decoy. This characteristic allows the RBC-NS to bind and neutralize toxins, auto-antibodies, and bacterial infections. The pore-forming toxins emitted by MRSA can be effectively absorbed and neutralized by RBC-NS.
Request a sample and discover the recent advances in methicillin-resistant Staphylococcus aureus infection treatment drugs @ Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report
The methicillin-resistant Staphylococcus aureus infection pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage methicillin-resistant Staphylococcus aureus infection products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the methicillin-resistant Staphylococcus aureus infection pipeline landscape.
Methicillin-Resistant Staphylococcus aureus Infection Overview
Methicillin-resistant Staphylococcus aureus (MRSA) infections are caused by bacteria that have attained resistance from several antibiotics that treat diseases caused by Staphylococcus bacteria. The common patients of Methicillin-resistant Staphylococcus aureus (MRSA) infections are patients that have been in hospitals or healthcare settings for a long duration where the bacteria is found commonly. MRSA infections are known as healthcare-associated MRSA (HA-MRSA) if infected in hospitals. Such infections can spread to healthcare workers through invasive procedures, which are further transmitted to several patients by touching and operating with bare hands.
Other MRSA infections occur in a considerable population of healthy people. People associated with community-associated MRSA (CA-MRSA) show symptoms appearing as painful skin boils. It further spreads through physical contact between individuals. The population at higher risk includes people surrounded by a significant number of people and childcare workers. MRSA infections might look like red bumps, pimples, or spider bites, accompanied by pus and fever.
Find out more about methicillin-resistant Staphylococcus aureus infection treatment drugs @ Drugs for Methicillin-Resistant Staphylococcus aureus Infection Treatment
A snapshot of the Methicillin-Resistant Staphylococcus aureus Infection pipeline drugs mentioned in the report:
Drug | Company | Phase | MoA | RoA |
Ceftobiprole | Basilea Pharmaceutica | Phase III | Cell wall inhibitors; Peptidyltransferase inhibitors | Intravenous |
CG 549 | CrystalGenomics
|
Phase II | Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors | Oral |
BCM-0184 | Biocidium Pharmaceuticals | Phase I | NA | Oral/Topical |
TRL1068 | Trellis Bioscience | Phase I | Bacterial biofilm inhibitors | Intravenous |
ALS 4 | Aptorum Group | Phase I | Bacterial virulence inhibitors | Oral |
EVX-B1 | Evaxion Biotech | Preclinical | Immunostimulants | NA |
Emricasan | Histogen | Preclinical | Apoptosis inhibitors; Caspase inhibitors | NA |
TarO inhibitor | Prokaryotics | Discovery | Cell membrane inhibitors; Cell wall inhibitors | NA |
Learn more about the emerging methicillin-resistant Staphylococcus aureus infection pipeline therapies @ Methicillin-Resistant Staphylococcus aureus Infection Clinical Trials
Methicillin-Resistant Staphylococcus aureus Infection Therapeutics Assessment
The methicillin-resistant Staphylococcus aureus infection pipeline report proffers an integral view of methicillin-resistant Staphylococcus aureus infection emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Pre-clinical, Discovery, Discontinued, Inactive, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical.
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Cell wall inhibitors; Peptidyltransferase inhibitors, Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors, Bacterial biofilm inhibitors, Bacterial virulence inhibitors, Immunostimulants, Apoptosis inhibitors; Caspase inhibitors, Cell membrane inhibitors; Cell wall inhibitors
- Key Methicillin-Resistant Staphylococcus aureus Infection Companies: Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
- Key Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapies: TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and others.
Dive deep into rich insights for new drugs for methicillin-resistant Staphylococcus aureus infection treatment; visit @ Methicillin-Resistant Staphylococcus aureus Infection Drugs
Table of Contents
1. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Introduction |
2. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Executive Summary |
3. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Overview |
4. | Analytical Perspective In-depth Commercial Assessment |
5. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics |
6. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Pre-registration) |
7. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Phase III) |
7.1 | Ceftobiprole: Basilea Pharmaceutica |
8. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Mid Stage Products (Phase II) |
8.1 | CG549: CrystalGenomics |
9. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Early Stage Products (Phase I) |
9.1 | TRL1068: Trellis Bioscience |
10. | Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics Assessment |
11. | Inactive Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline |
12. | Company-University Collaborations (Licensing/Partnering) Analysis |
13. | Key Companies |
14. | Key Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline |
15. | Unmet Needs |
16. | Market Drivers and Barriers |
17. | Future Perspectives and Conclusion |
18. | Analyst Views |
19. | Appendix |
For further information on the methicillin-resistant Staphylococcus aureus infection pipeline therapeutics, reach out @ Methicillin-Resistant Staphylococcus aureus Infection Treatment Drugs
Related Reports
Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast
Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the methicillin-resistant Staphylococcus aureus epidemiology trends.
Methicillin-Resistant Staphylococcus aureus Infection Market
Methicillin-Resistant Staphylococcus aureus Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key methicillin-resistant Staphylococcus aureus infection companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others.
Staphylococcus aureus Bacteremia Pipeline
Staphylococcus aureus Bacteremia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Staphylococcus aureus Bacteremia companies, including ContraFect, Armata Pharmaceuticals, iNtRON Biotechnology, Durata Therapeutics, Cipher Pharmaceuticals, XBiotech, Basilea Pharmaceutica, Genentech, among others.
Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline
Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Artificial Intelligence
QSAN Unveils Latest Solutions for AI Era at COMPUTEX 2024
Introducing Next-Gen NVMe Array and All-New Container Platform
TAIPEI, April 24, 2024 /PRNewswire/ — AI is sweeping the globe, transforming industries and spurring enterprises to adopt AI in business. As companies gear up to seize this incredible opportunity of rapid business growth, upgrading their IT infrastructure is the first step. At COMPUTEX 2024, QSAN will unveil state-of-the-art solutions to assist enterprises in the AI era.
Unparalleled Performance All NVMe Flash ArrayThe next-generation XCubeFAS 5226 is now delivering extremely fast performance. It features low latency, high throughput, and robust IOPs to accelerate demanding workloads for the upcoming AI era.
Innovative Container PlatformThe KubeSwift series is an innovative appliance that empowers SMBs with CaaS (Container as a Service) capabilities. This all-in-one solution streamlines containerized application deployment, management, and scaling, providing a robust foundation for modern IT infrastructures.
High Scalability Enterprise Unified StorageAs artificial intelligence continues to advance, the value of data will grow exponentially, driving the need for expanded storage capacity. XCubeNXT is an enterprise unified storage system with PB-level scalability, high availability, and multi-functional connectivity. It aims to prepare for storing massive amounts of material generated by AI.
Register for QSAN Tech Talk
QSAN will host tech talks to provide insights into storage technology and the future. Professionals will have in-depth discussions on topics such as AI applications, storage technology trends, market analysis, and prediction. Register for tech talk for more forecasts.
Make an Appointment with a QSAN Expert Consultant
Tailor-made storage consulting will also be available at COMPUTEX 2024. For the best chance of accelerating your business, make an appointment with a QSAN expert.
QSAN at 2024 COMPUTEX Information
Event Date: June 4 ~ 7, 2024Event Time: (GMT+8) 9:30 AM ~ 05:30 PMBooth No.: M1435a (AI Computing & System Integration)Location: 4F, Taipei Nangang Exhibition Center, Hall 1 (TaiNEX 1)Address: No.1, Jingmao 2nd Rd., Nangang District, Taipei City 115, Taiwan
QSAN Showroom for Tech Talk and Expert Consultant
Event Date: June 4 ~ 7, 2024Event Time: (GMT+8) 10:00 AM ~ 05:30 PMLocation: QSAN ShowRoomAddress: No. 2, Ln. 1, Fukang St., Nangang District, Taipei City 115, Taiwan
For more information, please visit: www.QSAN.com
Media Contacts Email: [email protected] Address: 4F., No.103, RuiHu Street, NeiHu District, Taipei, Taiwan11494 Phone: +886-2-7720-2118
View original content:https://www.prnewswire.co.uk/news-releases/qsan-unveils-latest-solutions-for-ai-era-at-computex-2024-302126012.html
Artificial Intelligence
Kanazawa University research: Biochemical tails tell a story
KANAZAWA, Japan, April 24, 2024 /PRNewswire/ — Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the use of high-speed atomic force microscopy helps to understand the crucial role played by certain biomolecules in DNA wrapping dynamics.
In plants and animals, the basic packaging units of DNA, which carry genetic information, are the so-called nucleosomes. A nucleosome consists of a segment of DNA wound around eight proteins known as histones. During gene expression (the process lying at the basis of protein production), nucleosomes are involved in various dynamical structural changes, such as nucleosome sliding, DNA unwrapping and other DNA–histone interactions. Of particular importance in these processes are the end structures, or tails, of the histones. Histone tails undergo chemical modifications, changing the histone’s functionality as needed. Detailed studies, and especially visualizations, of nucleosome dynamics are crucial for better understanding the role of histone tails. Mikihiro Shibata from Kanazawa University and colleagues have now succeeded in making video recordings of tail-less nucleosomes, showing that the absence of histone tails significantly increases a nucleosome’s dynamic activity.
The scientists used high-speed atomic force microscopy (HS-AFM), a powerful nanoimaging tool for visualizing molecular structures and their dynamics at high spatial and temporal resolution. For this, the nucleosomes needed to be put onto a substrate. Shibata and colleagues used a film of so-called pillar[5]arenes (molecules with a pentagonal tubular structure) as the substrate, forming an ideal surface as the nucleosomes are easily adsorbed to it without dynamical processes getting suppressed.
The researchers first looked at nucleosomes for which all eight histones lacked tails. Based on their HS-AFM observations, they concluded that nucleosome sliding and DNA unwrapping/rewrapping occurred more often than for normal (canonical) nucleosomes. This suggests that without tails, the histone–DNA interaction is weakened, leading to a situation in which DNA can more easily detach from the histones.
To better understand the roles of specific histone tails, Shibata and colleagues prepared nucleosomes where one type of histone was tailless. There are four different types of histones, called H2A, H2B, H3 and H4. HS-AFM experiments on the nucleosomes revealed that H2B and H3 tail-less nucleosomes showed an increased frequency of dynamics. Conversely, this means that canonical H2B and H3 histones are essential for nucleosome stability.
The scientists point out that they could not observe any actual motion of histone tails — most likely the temporal resolution of the study, 0.3 seconds, was much slower than the rate of the wrapping/unwrapping dynamics of the tails. Despite this limitation, the work of Shibata and colleagues clearly proves that the tails of H2B and H3 histones are the main contributors to nucleosome dynamics. Regarding future work, quoting the researchers, “a technique for tagging histone tail tips might enable HS-AFM to capture the movements of the histone tails themselves.”
Background
High-speed atomic force microscopy
The general principle of atomic force microscopy (AFM) is to make a very small tip scan the surface of a sample. During this horizontal (xy) scan, the tip, which is attached to a small cantilever, follows the sample’s vertical (z) profile, inducing a force on the cantilever that can be measured. The magnitude of the force at the xy position can be related to the z value; the xyz data generated during a scan then result in a height map providing structural information about the investigated sample. In high-speed-AFM (HS-AFM), the working principle is slightly more involved: the cantilever is made to oscillate near its resonance frequency. When the tip is moved around a surface, the variations in the amplitude (or the frequency) of the cantilever’s oscillation — resulting from the tip’s interaction with the sample’s surface — are recorded, as these provide a measure for the local z value. AFM does not involve lenses, so its resolution is not restricted by the so-called diffraction limit as in X-ray diffraction, for example.
HS-AFM results in a video, where the time interval between frames depends on the speed with which a single image can be generated (by xy-scanning the sample). Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time. Mikihiro Shibata and colleagues have now applied the method to study nucleosome dynamics in detail, and in particular the role of the molecular endings of histones — proteins that play a crucial role in DNA accessibility.
Reference
Shin Morioka, Takumi Oishi, Suguru Hatazawa, Takahiro Kakuta, Tomoki Ogoshi, Kenichi Umeda, Noriyuki Kodera, Hitoshi Kurumizaka, and Mikihiro Shibata. High-Speed Atomic Force Microscopy Reveals the Nucleosome Sliding and DNA Unwrapping/Wrapping Dynamics of Tail-less Nucleosomes, Nano Letters ,2024.
DOI: 10.1021/acs.nanolett.4c00801https://pubs.acs.org/doi/10.1021/acs.nanolett.4c00801
https://nanolsi.kanazawa-u.ac.jp/wp/wp-content/uploads/Figure-1-12.png Figure 1.
High-speed atomic force microscopy visualization of nucleosome dynamics with canonical (top) and tail-less (bottom) histones.© 2024 American Chemical Society
ContactHiroe YonedaSenior Specialist in Project Planning and OutreachNanoLSI Administration Office, Nano Life Science Institute (WPI-NanoLSI)Kanazawa UniversityKakuma-machi, Kanazawa 920-1192, JapanEmail: [email protected]: +81 (76) 234-4555
About Nano Life Science Institute (WPI-NanoLSI), Kanazawa University
Understanding nanoscale mechanisms of life phenomena by exploring “uncharted nano-realms”
Cells are the basic units of almost all life forms. We are developing nanoprobe technologies that allow direct imaging, analysis, and manipulation of the behavior and dynamics of important macromolecules in living organisms, such as proteins and nucleic acids, at the surface and interior of cells. We aim at acquiring a fundamental understanding of the various life phenomena at the nanoscale.https://nanolsi.kanazawa-u.ac.jp/en/
About the World Premier International Research Center Initiative (WPI)
The WPI program was launched in 2007 by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT) to foster globally visible research centers boasting the highest standards and outstanding research environments. Numbering more than a dozen and operating at institutions throughout the country, these centers are given a high degree of autonomy, allowing them to engage in innovative modes of management and research. The program is administered by the Japan Society for the Promotion of Science (JSPS).
See the latest research news from the centers at the WPI News Portal: https://www.eurekalert.org/newsportal/WPI
Main WPI program site: www.jsps.go.jp/english/e-toplevel
About Kanazawa University
As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.
The University is located on the coast of the Sea of Japan in Kanazawa – a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.http://www.kanazawa-u.ac.jp/e/
View original content:https://www.prnewswire.co.uk/news-releases/kanazawa-university-research-biochemical-tails-tell-a-story-302125876.html
Artificial Intelligence
Geek+ and System Teknik deploy first PopPick solution in the Nordics for the pharmacy group Med24.dk
DUSSELDORF, Germany, April 24, 2024 /PRNewswire/ — Geekplus, the global leader in mobile robot and smart logistics solutions, has deployed the first Shelf-to-Person PopPick project in the Nordics for one of the biggest online pharmacy wholesalers in the region, Med24.dk. System Teknik partnered on the Denmark project, which includes three PopPick stations and 30 Shelf-to-Person robots, bringing a flexible solution to a region where fixed automation still dominates.
“With the rise of e-commerce, Med24.dk had been struggling with huge sales growth coupled with fast delivery demands from customers in Denmark, Norway, Sweden searching for pharmacy, health and beauty products. Peak season events had also caused considerable strain to their operations,” said Blond Shkodrani, channel partner manager for the Nordics at Geekplus. “Due to their overwhelming success, Med24.dk needed a modular, automated order fulfillment solution for fast, efficient order fulfillment.”
The Geekplus modular Shelf-to-Person solution optimizes warehouse operations using mobile robots to transport shelves. In a region where fixed and cubic solutions have been the trend during recent years, Shelf-to-Person handles goods of all sizes while removing the need for infrastructure investment, making it the most flexible response to order fulfillment challenges.
PopPick workstations use two retrieval arms and four presentation locations to present pickers with multiple, moveable 78-tote racks at one time, resulting in an industry-leading throughput of 450 totes per hour. PopPick can store goods of all types and sizes; the solution is not limited to small pieces and improves ergonomics for workers while picking. It also takes up less space than traditional systems, so customers can use more stations without adding facility space.
“We are very pleased to invest in flooring robots from Geekplus,” said Med24.dk CEO Nils Træholt. “We believe that this new and innovative technology can help us realize our growth ambitions, while maintaining good delivery times for the benefit of our customers.”
Morten Kirch, System Teknik’s CSO, added: “Due to Med24.dk’s growth, we are thrilled to be able to deliver a tailor-made, automated solution that matches their needs.”
Geekplus offers a suite of Goods-to-Person mobile order fulfillment solutions — the only comprehensive robotic offering controlled by a single software platform.
“Through trusted partners like System Teknik, we’re showing customers all over Europe that Geekplus truly is a one-stop shop for modular warehouse automation,” Shkodrani said.
Photo – https://mma.prnewswire.com/media/2395198/Med24_Geekplus_PopPick.jpg Logo – https://mma.prnewswire.com/media/2373458/Geekplus_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/geek-and-system-teknik-deploy-first-poppick-solution-in-the-nordics-for-the-pharmacy-group-med24dk-302125816.html
-
Artificial Intelligence7 days ago
Huawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Uncategorized5 days ago
Generative AI gold rush drives IT spending — with payoff in question
-
Uncategorized5 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized5 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized5 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Artificial Intelligence5 days ago
Free Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.
-
Uncategorized5 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized5 days ago
The Ottawa Hospital doctors to try AI for patient notes